Back to top
more

ARK Genomic Revolution ETF: (ARKG)

(Real Time Quote from BATS) As of Nov 19, 2026 01:28 PM ET

$40.90 USD

40.9
2,360,397

-0.36 (-0.87%)

Volume: 2,360,397

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

NA

Zacks News

Neena Mishra headshot

Why You Should Invest in Genomics ETFs

Genomics ETFs have surged of late; here's why

Sweta Jaiswal, FRM headshot

Biotech ETFs to Shine on Coronavirus Antibodies Progress

With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.

Sweta Killa headshot

5 Sector ETFs Gaining in Double Digits to Start October

Wall Street registered back-to-back weekly gains primarily on the back of prospects for another round of fiscal stimulus from Congress.

Sweta Jaiswal, FRM headshot

Genomics ETFs Surge on Nobel Prize for Gene-Editing Pioneers

The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.

Sweta Jaiswal, FRM headshot

Biotech ETFs to Gain on Trump's COVID-19 Treatment Protocol

The progress in Trump's health condition and his treatment protocols are continuously under the purview of market participants and are impacting Wall Street movements.

Sweta Killa headshot

Healthcare ETFs Pop on Bristol Myers-MyoKardia Deal

These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.

Sweta Jaiswal, FRM headshot

Top-Performing Biotech ETFs Amid the Coronavirus Crisis

The race to introduce vaccine and treatment of coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.

Sweta Killa headshot

Top & Flop ETF Zones of First Nine Months of 2020

We have highlighted the best and worst-performing zones and their ETFs in the first nine months of 2020.

Sweta Jaiswal, FRM headshot

Biotech ETFs in Focus as the COVID-19 Vaccine Race Intensifies

Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.

Sweta Jaiswal, FRM headshot

How Will Biotech ETFs React to Vaccine Makers' Safety Pledge?

Nine vaccine developers have jointly pledged to observe high ethical standards in conducting clinical studies and manufacturing of vaccines.